Martinsried / Munich, Germany, Oct. 1, 2016 (GLOBE NEWSWIRE) -- Guselkumab Met Co-Primary Endpoints in Patients with Moderate to Severe Plaque Psoriasis
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Research & Development, LLC (Janssen) has reported positive results from a clinical phase 3 study with 837 patients examining guselkumab, a fully human antibody intended to target IL-23 identified from MorphoSys's HuCAL antibody library, in patients with moderate to severe plaque psoriasis.
Janssen presented the data from its "VOYAGE 1" study today in a late breaking session at the 25th congress of the European Academy of Dermatology and Venereology (EADV) in Vienna, Austria. The randomized, double-blind, placebo- and active-comparator-controlled study evaluated guselkumab, in comparison to placebo and the active comparator adalimumab (Humira®), in the treatment of moderate to severe plaque psoriasis.
"We are excited about the positive results released by our licensee Janssen with respect to guselkumab in the treatment of moderate to severe plaque psoriasis", said Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "We are proud of our long-standing collaboration with Janssen and we are looking forward to the further updates about the development of guselkumab going forward."
Further detailed information about the clinical study results can be found in a press release issued today by Janssen.
Psoriasis is an autoimmune disease which is characterized by patches of abnormal skin. These skin patches are typically red, itchy, and scaly. They may vary in severity from small and localized to complete body coverage. There are five main types of psoriasis: plaque, guttate, inverse, pustular, and erythrodermic. Plaque psoriasis, also known as psoriasis vulgaris, makes up about 90% of cases. It typically presents with red patches with white scales on top. Psoriasis is usually chronic and has a high morbidity and negative impact on patients' quality of life. In 2015 prevalence of the disease was 16 million patients in the seven major countries (USA, Japan, France, Germany, Italy, Spain, and Great Britain), as estimated by independent market intelligence experts.
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.
Humira® is a registered trademarks of AbbVie Inc.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Associate Director Corporate Communications & IR
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
Media Release (PDF) http://hugin.info/130295/R/2046046/764507.pdfGlobeNewswire
Last updated on: 03/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.